Esperion Therapeutics, Inc. Q3 2025 Earnings Recap

ESPR Q3 2025 November 7, 2025

Get alerts when ESPR reports next quarter

Esperion Therapeutics reported a strong Q3 2025 with a 69% year-over-year revenue increase, leveraging strategic investments and marketing efforts to drive prescription growth amid heightened recognition of its bempedoic acid products.

Earnings Per Share Miss

$-0.16 vs $-0.09 est.

-77.8% surprise

Revenue Miss

87309000 vs 165122090 est.

-47.1% surprise

Market Reaction

1-Day +6.4%

5-Day +21.2%

30-Day +46.4%

See ESPR alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total revenue reached $87.3 million, driven by a 31% year-over-year growth in U.S. net product revenue.
The company secured agreements with four generic manufacturers to protect its NEXLETOL franchise through April 2040, enhancing long-term value.
Increased prescriber engagement and strategic marketing aimed at statin-intolerant patients contributed to improved brand awareness and prescription growth.
The introduction of bempedoic acid products in ESC/EAS guidelines marks a significant clinical validation, with expectations for U.S. guideline inclusion in early 2026.
An 87% average approval rate for Medicare coverage reflects successful efforts in enhancing patient access.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ESPR on AllInvestView.